Investment Thesis
Aspira Women's Health is in severe financial distress with negative stockholders' equity of -4.3M, indicating liabilities exceed assets. The company is burning cash at an alarming rate (-5.1M FCF) while revenue has collapsed 56.4% YoY, generating only 311K in the latest period, making near-term viability questionable.
Strengths
- Maintains positive current ratio of 1.39x suggesting short-term liquidity remains adequate
- Still holds 3.8M in cash providing runway for operations
- Gross profit positive at 4.5M indicating underlying product economics are present
Risks
- Negative stockholders' equity of -4.3M represents technical insolvency with liabilities exceeding assets
- Severe revenue decline of 56.4% YoY with only 311K revenue in latest period indicates collapsing business
- Operating cash burn of -5.0M combined with minimal revenue suggests company will exhaust cash within 9-12 months without turnaround
- Operating losses of -6.6M and net losses of -9.4M demonstrate inability to achieve profitability at current scale
- No insider buying activity in 90 days suggests management lacks confidence
Key Metrics to Watch
- Monthly revenue trend and stabilization timeline
- Operating cash burn rate and runway remaining with current cash balance
- Path to profitability or evidence of business stabilization
- Changes in stockholders' equity and debt restructuring plans
Financial Metrics
Revenue
311.0K
Net Income
-9.4M
EPS (Diluted)
$-0.30
Free Cash Flow
-5.1M
Total Assets
7.3M
Cash
3.8M
Profitability Ratios
Gross Margin
1,439.5%
Operating Margin
-2,131.5%
Net Margin
-3,026.0%
ROE
N/A
ROA
-129.0%
FCF Margin
-1,625.7%
Balance Sheet & Liquidity
Current Ratio
1.39x
Quick Ratio
1.32x
Debt/Equity
N/A
Debt/Assets
159.5%
Interest Coverage
-32.18x
Long-term Debt
1.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T12:14:11.857114 |
Data as of: 2025-09-30 |
Powered by Claude AI